• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

间充质干细胞缺陷通过TNFAIP3/NF-κB/SMAD途径影响免疫性血小板减少症患者的巨核细胞生成。

Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the TNFAIP3/NF-κB/SMAD pathway in patients with immune thrombocytopenia.

作者信息

He Yun, Xu Lin-Lin, Feng Fei-Er, Wang Qian-Ming, Zhu Xiao-Lu, Wang Chen-Cong, Zhang Jia-Min, Fu Hai-Xia, Xu Lan-Ping, Liu Kai-Yan, Huang Xiao-Jun, Zhang Xiao-Hui

机构信息

Peking University People's Hospital, Peking University Institute of Haematology, Beijing, China.

Beijing Key Laboratory of Haematopoietic Stem Cell Transplantation, Beijing, China.

出版信息

Br J Haematol. 2018 Feb;180(3):395-411. doi: 10.1111/bjh.15034. Epub 2018 Jan 12.

DOI:10.1111/bjh.15034
PMID:29327472
Abstract

Immune thrombocytopenia (ITP) is an autoimmune disease. Mesenchymal stem cells (MSCs) play important roles in the physiology and homeostasis of the haematopoietic system, including supporting megakaryocytic differentiation from CD34 haematopoietic progenitor cells. Tumour necrosis factor alpha-induced protein 3 (TNFAIP3, also termed A20) plays a key role in terminating NF-κB signalling. Human genetic studies showed that the polymorphisms of the TNFAIP3 gene may contribute to ITP susceptibility. In this study, we showed a significant decrease in TNFAIP3 and increase in NF-κB/SMAD7 in ITP-MSCs. In co-cultures with CD34 cells, NF-κB was overexpressed in MSCs from healthy controls (HC-MSCs) after transfection with NFKBIA (IκB)-specific short hairpin (sh)RNAs, resulting in MSC deficiency and a reduction in megakaryocytic differentiation and thrombopoiesis. Knockdown of TNFAIP3 expression using TNFAIP3-specific shRNAs in HC-MSCs affected megakaryocytopoiesis. However, IKBKB knockdown corrected megakaryocytopoiesis inhibition in the ITP-MSCs by decreasing NF-κB expression. Amplified TNFAIP3 expression in ITP-MSCs by TNFAIP3 cDNA can facilitate megakaryocyte differentiation. shRNA-mediated knockdown of SMAD7 expression rescued the impaired MSC function in ITP patients. Therefore, we demonstrate that a pathological reduction in TNFAIP3 levels induced NF-κB/SMAD7 pathway activation, causing a deficiency in MSCs in ITP patients. The ability of ITP-MSCs to support megakaryocytic differentiation and thrombopoiesis of CD34 cells was impaired.

摘要

免疫性血小板减少症(ITP)是一种自身免疫性疾病。间充质干细胞(MSC)在造血系统的生理和稳态中发挥重要作用,包括支持CD34造血祖细胞向巨核细胞分化。肿瘤坏死因子α诱导蛋白3(TNFAIP3,也称为A20)在终止NF-κB信号传导中起关键作用。人类遗传学研究表明,TNFAIP3基因的多态性可能与ITP易感性有关。在本研究中,我们发现ITP-MSC中TNFAIP3显著降低,NF-κB/SMAD7升高。在与CD34细胞共培养时,用NFKBIA(IκB)特异性短发夹(sh)RNA转染后,健康对照(HC-MSC)的MSC中NF-κB过表达,导致MSC缺陷以及巨核细胞分化和血小板生成减少。在HC-MSC中使用TNFAIP3特异性shRNA敲低TNFAIP3表达会影响巨核细胞生成。然而,敲低IKBKB可通过降低NF-κB表达纠正ITP-MSC中的巨核细胞生成抑制。通过TNFAIP3 cDNA扩增ITP-MSC中的TNFAIP3表达可促进巨核细胞分化。shRNA介导的敲低SMAD7表达可挽救ITP患者受损的MSC功能。因此,我们证明TNFAIP3水平的病理性降低诱导NF-κB/SMAD7途径激活,导致ITP患者的MSC缺陷。ITP-MSC支持CD34细胞巨核细胞分化和血小板生成的能力受损。

相似文献

1
Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the TNFAIP3/NF-κB/SMAD pathway in patients with immune thrombocytopenia.间充质干细胞缺陷通过TNFAIP3/NF-κB/SMAD途径影响免疫性血小板减少症患者的巨核细胞生成。
Br J Haematol. 2018 Feb;180(3):395-411. doi: 10.1111/bjh.15034. Epub 2018 Jan 12.
2
The Mechanistic Effects and Clinical Applications of Various Derived Mesenchymal Stem Cells in Immune Thrombocytopenia.各种衍生间充质干细胞在免疫性血小板减少症中的作用机制及临床应用。
Acta Haematol. 2022;145(1):9-17. doi: 10.1159/000517989. Epub 2021 Aug 10.
3
Platelet-Derived Growth Factor-BB Protects Mesenchymal Stem Cells (MSCs) Derived From Immune Thrombocytopenia Patients Against Apoptosis and Senescence and Maintains MSC-Mediated Immunosuppression.血小板衍生生长因子-BB保护免疫性血小板减少症患者来源的间充质干细胞免受凋亡和衰老,并维持间充质干细胞介导的免疫抑制。
Stem Cells Transl Med. 2016 Dec;5(12):1631-1643. doi: 10.5966/sctm.2015-0360. Epub 2016 Jul 28.
4
Impaired Function of Bone Marrow Mesenchymal Stem Cells from Immune Thrombocytopenia Patients in Inducing Regulatory Dendritic Cell Differentiation Through the Notch-1/Jagged-1 Signaling Pathway.免疫性血小板减少症患者骨髓间充质干细胞通过 Notch-1/Jagged-1 信号通路诱导调节性树突状细胞分化功能障碍。
Stem Cells Dev. 2017 Nov 15;26(22):1648-1661. doi: 10.1089/scd.2017.0078. Epub 2017 Oct 24.
5
[Functional deficiency of bone marrow mesenchymal stem cells in patients with immune thrombocytopenia: An update].免疫性血小板减少症患者骨髓间充质干细胞的功能缺陷:最新进展
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2022 Mar;38(3):275-280.
6
The defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia.慢性免疫性血小板减少症患者骨髓来源的间充质干细胞存在缺陷。
Autoimmunity. 2014 Dec;47(8):519-29. doi: 10.3109/08916934.2014.938320. Epub 2014 Jul 14.
7
CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-κB in the bone marrow failure of acquired aplastic anemia.CD106是骨髓间充质干细胞通过NF-κB在获得性再生障碍性贫血骨髓衰竭中的一种新型介质。
Stem Cell Res Ther. 2017 Aug 1;8(1):178. doi: 10.1186/s13287-017-0620-4.
8
The polymorphisms of tumor necrosis factor-induced protein 3 gene may contribute to the susceptibility of chronic primary immune thrombocytopenia in Chinese population.肿瘤坏死因子诱导蛋白3基因多态性可能与中国人群慢性原发性免疫性血小板减少症的易感性有关。
Platelets. 2016;27(1):26-31. doi: 10.3109/09537104.2015.1022142. Epub 2015 Mar 25.
9
Activation of the NF-κB Pathway and Heterozygous Deletion of TNFAIP3 (A20) Confer Superior Survival in Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.NF-κB 通路的激活和 TNFAIP3(A20)的杂合性缺失赋予鼻型结外自然杀伤/T 细胞淋巴瘤更好的生存优势。
Am J Clin Pathol. 2019 Jul 5;152(2):243-252. doi: 10.1093/ajcp/aqz041.
10
Synergistic activation of NF-κB by TNFAIP3 (A20) reduction and UBE2L3 (UBCH7) augment that synergistically elevate lupus risk.TNFAIP3(A20)减少和 UBE2L3(UBCH7)增加协同激活 NF-κB,从而协同提高狼疮风险。
Arthritis Res Ther. 2020 Apr 25;22(1):93. doi: 10.1186/s13075-020-02181-4.

引用本文的文献

1
OX40 ligand promotes follicular helper T cell differentiation and development in mice with immune thrombocytopenia.OX40配体促进免疫性血小板减少症小鼠中滤泡辅助性T细胞的分化和发育。
J Zhejiang Univ Sci B. 2025 Mar 6;26(3):240-253. doi: 10.1631/jzus.B2300947.
2
YTHDC1 Mitigates Apoptosis in Bone Marrow Mesenchymal Stem Cells by Inhibiting and Augmenting Cardiac Function Following Myocardial Infarction.YTHDC1 通过抑制和增强心肌梗死后的心脏功能减轻骨髓间充质干细胞凋亡。
Cell Transplant. 2024 Jan-Dec;33:9636897241290910. doi: 10.1177/09636897241290910.
3
Bioengineered niches that recreate physiological extracellular matrix organisation to support long-term haematopoietic stem cells.
生物工程化小生境,重建生理细胞外基质组织,以支持长期造血干细胞。
Nat Commun. 2024 Jul 10;15(1):5791. doi: 10.1038/s41467-024-50054-0.
4
Identification of ORM1, vWF, SPARC, and PPBP as immune-related proteins involved in immune thrombocytopenia by quantitative LC-MS/MS.通过定量液相色谱-串联质谱法鉴定ORM1、血管性血友病因子(vWF)、富含半胱氨酸的酸性分泌蛋白(SPARC)和血小板碱性蛋白(PPBP)为参与免疫性血小板减少症的免疫相关蛋白。
Clin Proteomics. 2023 Jun 24;20(1):24. doi: 10.1186/s12014-023-09413-0.
5
All-trans retinoic acid added to treatment of primary immune thrombocytopenia: a systematic review and meta-analysis.全反式维甲酸联合治疗原发免疫性血小板减少症:系统评价和荟萃分析。
Ann Hematol. 2023 Jul;102(7):1695-1704. doi: 10.1007/s00277-023-05263-w. Epub 2023 May 11.
6
Therapeutic potential of MSCs and MSC-derived extracellular vesicles in immune thrombocytopenia.间充质干细胞及其衍生的细胞外囊泡在免疫性血小板减少症中的治疗潜力。
Stem Cell Res Ther. 2023 Apr 12;14(1):79. doi: 10.1186/s13287-023-03323-6.
7
Extracellular vesicles and their cells of origin: Open issues in autoimmune diseases.细胞外囊泡及其来源细胞:自身免疫性疾病中的未解决问题。
Front Immunol. 2023 Mar 8;14:1090416. doi: 10.3389/fimmu.2023.1090416. eCollection 2023.
8
Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells.艾曲泊帕可增强间充质干/基质细胞的造血支持能力。
Ther Adv Hematol. 2022 Dec 26;13:20406207221142137. doi: 10.1177/20406207221142137. eCollection 2022.
9
TNFAIP3 promotes ALDH-positive breast cancer stem cells through FGFR1/MEK/ERK pathway.肿瘤坏死因子相关凋亡诱导配体蛋白 3 通过成纤维细胞生长因子受体 1/丝裂原活化蛋白激酶/细胞外信号调节激酶通路促进 ALDH 阳性乳腺癌干细胞。
Med Oncol. 2022 Sep 29;39(12):230. doi: 10.1007/s12032-022-01844-3.
10
Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?难治性 ITP 的当前治疗策略和观点:最近我们学到了什么?
Front Immunol. 2022 Aug 8;13:953716. doi: 10.3389/fimmu.2022.953716. eCollection 2022.